Literature DB >> 27085557

High-resolution telomere fluorescence in situ hybridization reveals intriguing anomalies in germ cell tumors.

Mohammed Talha Shekhani1, John R Barber2, Stephania M Bezerra3, Christopher M Heaphy1, Nilda Diana Gonzalez Roibon3, Diana Taheri3, Leonardo O Reis3, Gunes Guner3, Corinne E Joshu4, George J Netto5, Alan K Meeker6.   

Abstract

Testicular germ cell tumor (TGCT) is the most common malignancy of young men. Most patients are completely cured, which distinguishes these from most other malignancies. Orchiectomy specimens (n=76) were evaluated using high-resolution (single-cell discriminative) telomere-specific fluorescence in situ hybridization (FISH) with simultaneous Oct4 immunofluorescence to describe telomere length phenotype in TGCT neoplastic cells. For the first time, the TGCT precursor lesion, germ cell neoplasia in situ (GCNIS) is also evaluated in depth. The intensity of the signals from cancerous cells was compared to the same patient's reference cells-namely, healthy germ cells (defined as "medium" length) and interstitial/somatic cells (defined as "short" telomere length). We observed short telomeres in most GCNIS and pure seminomas (P=.006 and P=.0005, respectively). In contrast, nonseminomas displayed longer telomeres. Lesion-specific telomere lengths were documented in mixed tumor cases. Embryonal carcinoma (EC) demonstrated the longest telomeres. A fraction of EC displays the telomerase-independent alternative lengthening of telomeres (ALT) phenotype (24% of cases). Loss of ATRX or DAXX nuclear expression was strongly associated with ALT; however, nuclear expression of both proteins was retained in half of ALT-positive ECs. The particular distribution of telomere lengths among TGCT and GCNIS precursors implicate telomeres anomalies in pathogenesis. These results may advise management decisions as well.
Copyright © 2016. Published by Elsevier Inc.

Entities:  

Keywords:  Embryonal carcinoma; FISH, alternative lengthening of telomeres (ALT); Germ cell neoplasia in situ (GCNIS); Oct4; Seminoma; Telomere; Testicular germ cell tumor (TGCT)

Mesh:

Substances:

Year:  2016        PMID: 27085557     DOI: 10.1016/j.humpath.2016.03.015

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  7 in total

1.  Evaluation of telomere length in human cardiac tissues using cardiac quantitative FISH.

Authors:  Maryam Sharifi-Sanjani; Alan K Meeker; Foteini Mourkioti
Journal:  Nat Protoc       Date:  2017-08-17       Impact factor: 13.491

Review 2.  Cancer telomeres and white crows.

Authors:  Alan K Meeker
Journal:  Am J Clin Exp Urol       Date:  2018-04-01

Review 3.  Distinct telomere length and molecular signatures in seminoma and non-seminoma of testicular germ cell tumor.

Authors:  Hua Sun; Pora Kim; Peilin Jia; Ae Kyung Park; Han Liang; Zhongming Zhao
Journal:  Brief Bioinform       Date:  2019-07-19       Impact factor: 11.622

Review 4.  The Role of ATRX in the Alternative Lengthening of Telomeres (ALT) Phenotype.

Authors:  João P Amorim; Gustavo Santos; João Vinagre; Paula Soares
Journal:  Genes (Basel)       Date:  2016-09-19       Impact factor: 4.096

5.  Cardiomyocyte-Specific Telomere Shortening is a Distinct Signature of Heart Failure in Humans.

Authors:  Maryam Sharifi-Sanjani; Nicholas M Oyster; Elisia D Tichy; Kenneth C Bedi; Ofer Harel; Kenneth B Margulies; Foteini Mourkioti
Journal:  J Am Heart Assoc       Date:  2017-09-07       Impact factor: 5.501

6.  Single Stem Cell Imaging and Analysis Reveals Telomere Length Differences in Diseased Human and Mouse Skeletal Muscles.

Authors:  Elisia D Tichy; David K Sidibe; Matthew T Tierney; Michael J Stec; Maryam Sharifi-Sanjani; Harish Hosalkar; Scott Mubarak; F Brad Johnson; Alessandra Sacco; Foteini Mourkioti
Journal:  Stem Cell Reports       Date:  2017-09-07       Impact factor: 7.765

Review 7.  Telomere Maintenance in Pediatric Cancer.

Authors:  Sandra Ackermann; Matthias Fischer
Journal:  Int J Mol Sci       Date:  2019-11-20       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.